February 23rd 2023
February 23rd 2023
Cancer Gene Profiling Test Can Open Doors to New Targeted Therapies
December 27th 2017While FoundationOne CDx, the comprehensive companion diagnostic test for solid tumors, gives patients the ability to be accurately matched with a targeted therapy, it also has potential benefits for patients with a less common types of cancers, said Stuart Goldberg, MD, chief scientific officer, Cota, in an interview with The American Journal of Managed Care®.
Read More
Dr Derek Raghavan: Ensuring Guidelines Are Implemented and Followed
December 22nd 2017Electronic health records can be used to measure and record how guidelines are being implemented and followed, but more government intervention is needed to regulate electronic health records and set standards, Derek Raghavan, MD, PhD, FACP, FRACP, president, Carolinas HealthCare System's Levine Cancer Institute.
Watch
Trends in Bisphosphonate Initiation Within an Integrated Healthcare Delivery System
The authors observed a marked shift toward treatment of higher-risk subsets of younger postmenopausal women (with prior fracture and/or with osteoporosis), and away from women at lower risk.
Read More
Real-World Economic Value of a 21-Gene Assay in Early-Stage Breast Cancer
Universal gene expression profiling of patients with stage II breast cancer resulted in outpatient savings of $11,000 (inclusive of testing costs) within 6 months of initiation of medical therapy.
Read More
Impact of Statin Guidelines on Statin Utilization and Costs in an Employer-Based Primary Care Clinic
Adherence to clinical guidelines in practice is often suboptimal and controversial. This study compares actual statin utilization and cost with full adoption of major clinical guidelines in a real-world population.
Read More
Conceptual Paper Proposes Four Cost-Reducing Interventions for In Vitro Diagnostics
December 14th 2017US healthcare spending is on the rise, and is expected to comprise over 20% of the gross domestic product by 2025. Current expenditures are expected to double by 2060 if the pace of spending in the past decade continues. In this healthcare landscape, in vitro diagnostics (IVD) have increasingly become the subject of scrutiny, as IVDs are perceived as contributing to soaring costs.
Read More
New Treatment Paradigm Supersedes ABVD in Advanced Hodgkin Lymphoma: The ECHELON-1 Study
December 13th 2017Including the modified brentuximab antibody in the treatment regimen improved modified progression-free survival by 5%, although the rates of neutropenia and infections were higher in patients administered the brentuximab-containing regimen.
Read More
Dr Derek Raghavan Outlines Challenges to Implementing Evidence-Based Guidelines
December 10th 2017Physician belief in the art of medicine is running up against the challenge of costs being shifted to patients and health systems and the desire of payers to have less variation in care, said Derek Raghavan, MD, PhD, FACP, FRACP, president, Carolinas HealthCare System's Levine Cancer Institute.
Watch
How Physicians Handle Differing Guidelines on Breast Cancer Screening Recommendations
December 6th 2017WIth different societies and organizations releasing contrary guidelines around breast cancer screening, experience with past patients or friends and family members could influence physicians' decisions around when to start screening mammography.
Read More
First-of-a-Kind Companion Test for Cancer Gene Profiling Gets FDA Approval
December 5th 2017The FDA has approved Foundation Medicine's FoundationOne CDx, the first-of-a-kind comprehensive companion diagnostic test for solid tumors. The test looks for hundreds of cancer genes, providing healthcare professionals with a more complete picture of what's causing tumor growth and guidance for treatment decisions.
Read More